| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.0028 | 1 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | JQ-1:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.0013 | 1 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.0013 | 1 |